Richard Schutter - Bausch Health Independent Director
| BHC Stock | USD 7.97 0.21 2.57% |
Director
Mr. Richard U. De Schutter is an Independent Director of the Company. He has served on the Board since January 2017. Prior to his retirement, Mr. De Schutter served as the Chairman and CEO of DuPont Pharmaceuticals Company from July 2000 until its acquisition by BristolMyers Squibb in October 2001. Mr. De Schutter was also a director and Chief Administrative Officer of Pharmacia Corporationrationration, which was created through the merger of Monsanto Company and Pharmacia Upjohn in 2000. Prior to this merger, Mr. De Schutter was a director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle Co., Monsantos wholly owned pharmaceutical subsidiary. Mr. De Schutter earned a BS degree in 1963, and a MS Degree in Chemical Engineering in 1965 from the University of Arizona. Since 2007, Mr. De Schutter has served as a director of AuVen Therapeutics, a private equity company focused on the healthcare industry. He has also served as a director of Applied Silver, Inc., a private biotechnology company, since 2016. He previously served as Chairman of Incyte Corporation from 2003 to 2015, as Chairman of Durata Therapeutics Inc. from 2012 to 2014, Chairman of Navicure, Inc. from 2002 to 2016, and Chairman of Sprout Pharmaceuticals, Inc. from 2011 to 2015. Mr. De Schutter was also a director of Smith Nephew plc from 2001 to 2014, during which time he also served as the Lead Independent Director from 2011 to 2014. since 2017.
| Age | 79 |
| Tenure | 7 years |
| Phone | 514 744 6792 |
| Web | https://www.bauschhealth.com |
Bausch Health Management Efficiency
The company has Return on Asset of 0.0415 % which means that on every $100 spent on assets, it made $0.0415 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (23.0454) %, meaning that it generated no profit with money invested by stockholders. Bausch Health's management efficiency ratios could be used to measure how well Bausch Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Greisch | Catalent | 65 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Nechemia Peres | Teva Pharma Industries | 61 | |
| Rolf Classon | Catalent | 75 | |
| Louise Parent | Zoetis Inc | 69 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Michael Barber | Catalent | 60 | |
| Gregory Lucier | Catalent | 56 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Rosemary Crane | Teva Pharma Industries | 60 | |
| JeanMichel Halfon | Teva Pharma Industries | 68 | |
| Robert Scully | Zoetis Inc | 71 | |
| Gerald Lieberman | Teva Pharma Industries | 73 | |
| Jack Stahl | Catalent | 67 | |
| Perry Nisen | Teva Pharma Industries | 64 | |
| Koji Hatsukawa | Takeda Pharmaceutical Co | 68 | |
| Gregory Norden | Zoetis Inc | 62 | |
| Roberto Mignone | Teva Pharma Industries | 48 | |
| Madhavan Balachandran | Catalent | 69 | |
| Sanjay Khosla | Zoetis Inc | 68 | |
| Jerome Hauer | Emergent Biosolutions | 68 | |
Management Performance
| Return On Equity | -23.05 | ||||
| Return On Asset | 0.0415 |
Bausch Health Companies Leadership Team
Elected by the shareholders, the Bausch Health's board of directors comprises two types of representatives: Bausch Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bausch. The board's role is to monitor Bausch Health's management team and ensure that shareholders' interests are well served. Bausch Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bausch Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| D Hale, Independent Director | ||
| Jeff Hartness, Commercial Access | ||
| John Barresi, Controller, VP | ||
| Garen Sarafian, VP Relations | ||
| Sarah Kavanagh, Independent Director | ||
| Arthur Shannon, IR Contact Officer | ||
| Tage MD, Chief RD | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Robert Butz, VP Affairs | ||
| Paul Herendeen, Chief Financial Officer, Executive Vice President | ||
| Brett Icahn, Independent Director | ||
| Richard Schutter, Independent Director | ||
| Seana Carson, Executive Counsel | ||
| Josh Coyle, Senior Salix | ||
| Amy Wechsler, Independent Director | ||
| Graham Jackson, Senior Officer | ||
| Sam Will, Senior Vice President - Finance, Chief Accounting Officer, Controller | ||
| Robert Power, Independent Director | ||
| Thomas Vadaketh, Ex CFO | ||
| Argeris Karabelas, Independent Director | ||
| Kathleen Fitzpatrick, Executive Officer | ||
| Joseph Gordon, President and Co-Head Bausch + Lomb/International | ||
| Jiny MBA, Senior Medical | ||
| Christina Ackermann, Executive Vice President, General Counsel and Head of Commercial Operations | ||
| William Woodfield, Senior Treasurer | ||
| Thomas Ross, Lead Independent Director | ||
| Donald Pearl, Senior Dermatologics | ||
| JeanJacques Charhon, Chief Officer | ||
| Andrew Eschenbach, Independent Director | ||
| Mirza Dautbegovic, Executive COO | ||
| Joseph Papa, Chairman of the Board, Chief Executive Officer | ||
| Aimee Lenar, Executive Pharma | ||
| John Paulson, Independent Director | ||
| Steven Miller, Independent Director | ||
| Thomas Appio, Executive Vice President Company Group Chairman, International | ||
| Robert Spurr, President - Salix | ||
| Cees Heiman, Senior Canada | ||
| Russel Robertson, Independent Director |
Bausch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bausch Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.05 | ||||
| Return On Asset | 0.0415 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 23.73 B | ||||
| Shares Outstanding | 367.8 M | ||||
| Shares Owned By Insiders | 11.08 % | ||||
| Shares Owned By Institutions | 71.40 % | ||||
| Number Of Shares Shorted | 11.65 M | ||||
| Price To Earning | 9.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bausch Health Companies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Health Companies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Health Companies Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.